Claims for Patent: 10,000,547
✉ Email this page to a colleague
Summary for Patent: 10,000,547
| Title: | Peptides and combination of peptides for use in immunotherapy against various tumors |
| Abstract: | The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. |
| Inventor(s): | Mahr; Andrea (Tuebingen, DE), Weinschenk; Toni (Aichwald, DE), Schoor; Oliver (Tuebingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Munich, DE), Stevermann; Lea (Tuebingen, DE) |
| Assignee: | IMMATICS BIOTECHNOLOGY GMBH (Tuebingen, DE) |
| Application Number: | 15/083,075 |
| Patent Claims: | 1. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a composition comprising a population of activated T
lymphocytes that selectively recognize cells in the patient that aberrantly express a peptide, wherein the peptide consists of the amino acid sequence of YLMDDFSSL (SEQ ID NO: 21), wherein said cancer is selected from the group consisting of
hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate
cancer (PCA), ovarian cancer (OC), melanoma, breast cancer, chronic lymphocytic leukemia (CLL), Merkel cell carcinoma (MCC), small cell lung cancer (SCLC), Non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), gallbladder cancer and
cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC), wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC
class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide.
2. The method of claim 1, wherein the T cells are autologous to the patient. 3. The method of claim 1, wherein the T cells are obtained from a healthy donor. 4. The method of claim 1, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells. 5. The method of claim 1, further comprising expanding T cells in vitro. 6. The method of claim 1, wherein the peptide is in a complex with an MHC molecule. 7. The method of claim 1, wherein the composition further comprises an adjuvant. 8. The method of claim 7, wherein the adjuvant is selected from the group consisting of imiquimod, resiguimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG, oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with PLG and virosomes. 9. The method of claim 1, wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide. 10. The method of claim 9, wherein the antigen presenting cell is a dendritic cell or a macrophage. 11. The method of claim 1, further comprising stimulating the activated T cells in the presence of an anti-CD28 antibody and IL-12 to clonally expand the T cells. 12. The method of claim 1, wherein the population of activated T cells comprises CD8-positive cells. 13. The method of claim 1, wherein the contacting is in vitro. |
Details for Patent 10,000,547
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | February 26, 2004 | 10,000,547 | 2035-03-27 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Showing 1 to 1 of 1 entries
